Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. - Wikidata - wikimedia - TriplyDB

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.

http://www.wikidata.org/entity/Q46167132

about

Promising Therapy Candidates for Liver Fibrosis New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress Pathophysiology of portal hypertension Cancer and liver cirrhosis: implications on prognosis and management Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Clinical Advancements in the Targeted Therapies against Liver Fibrosis.Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.Angiogenesis and liver fibrosis Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Future therapy of portal hypertension in liver cirrhosis - a guess.Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis.Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices.Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure.Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis.Ischemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats Targeted therapies for hepatocellular carcinoma.Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.

P2860

Q26766727-6FC92397-ABCC-49B2-AB0D-63422FA2E08B Q26772800-4E12D068-C518-4E50-9EE9-84CD99773083 Q26797581-85874C9F-035A-475C-8438-5D51C4E64A89 Q27013565-A24067AA-B895-46C4-9D89-BD4816C884F9 Q27023122-BE66A74A-0DAD-4200-AA51-9A184721619D Q27026406-B60FCC41-47E8-4D32-8E26-38B3BD6EAE8B Q28068579-1AE742ED-B73E-4A28-8FFD-C975B7B27C7D Q28068710-B9CCB0E2-E3AA-46D1-8FB7-A2F3FCCEA900 Q28078684-25A6DF93-BF98-45DA-9653-AB517B56751E Q28082065-0F5A3509-EBA4-4C51-ADF2-7EA0AFB2EAC8 Q28082569-BA492E42-CE5D-468D-84B5-E9B3A51FAB21 Q28272678-3E8BFC73-BAB5-4637-8A15-B2E3027DCA6D Q28536257-B5AA4F5F-A741-440D-AED5-AB44538E63A9 Q30465168-FF4E134D-6FF7-4007-90CE-6277BB6C73ED Q33702040-33E8336F-E9A7-4398-BCF9-80EF84F1D64F Q33826258-AA5E7B06-AC99-4515-8AF3-9E3AD103D42A Q34321931-8CAE61CD-260C-4A8C-B038-BAF2CD1E4DAD Q34352802-F7891557-47A4-457A-9642-EDB44974E374 Q34446521-4603435E-56E9-4A84-862C-2253CACFDBB6 Q34558284-67F3C5E3-FA21-4897-BDFD-DDE3D2D3EB8E Q34902424-858854F2-33CA-4922-89C4-1620D2CEEBE7 Q34983459-194ED264-9D23-4B53-890B-6267A80A59A3 Q35131876-4FE3DB5A-257C-4D5C-B01F-3D01AF70487A Q35136411-8D181FC7-80BD-4FBF-A5AA-0CFD22C2293A Q35154961-FF0D9991-5D97-4A94-87DB-7658109D3B42 Q35541817-E61FA0A6-E88A-4715-8C9F-B875B7544825 Q35560583-5FDA843E-60E4-4416-A7FF-663804BEE183 Q35651447-503BAEA0-25EA-46F0-B13A-9CB9CACFC0C4 Q35740334-55C061D0-E459-4E91-A595-A3BF17C1C5CE Q35842553-642CBE5D-6691-4778-B690-C7B9DA6882E5 Q35886555-E714C69F-93F0-4DF5-894A-EE9B77DF0B1A Q35906919-69AB28A9-331F-464C-9667-6A6369A36499 Q36180467-FB945D5C-65A3-429D-99B8-EF3C9B066094 Q36345910-9519BAE8-F5C2-4DBA-BDD2-038E5492DC28 Q36625697-ED1A99B7-84FF-4A1D-8CCB-9C84603299EA Q36746393-A3B71F65-3659-4F58-9B55-EC10DB9778E7 Q36928888-419F0E14-C23F-43AF-9D72-F97989BDD28B Q36973713-AAE973CA-79D7-4712-9186-51F14BD86938 Q37045749-E951CE78-6FFB-4214-A9AE-3C09E249277F Q37262768-D0B512C7-EF26-4F49-A1D3-CCEA11F15721

P2860

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.

http://www.wikidata.org/entity/Q46167132

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@en

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@nl

type

label

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@en

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@nl

prefLabel

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@en

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@nl

P1433

Q46167132-2E6BB3A1-97BD-458B-9141-CF320E1E4A7A

P1476

Q46167132-270819EF-33B2-4D90-A1A2-42A13C9DF08E

P2093

Q46167132-28BC897D-86BB-45A8-A3DF-9187C1B278C2

Q46167132-56F1C2DD-3F69-429D-82D4-0DC4C6CF422C

Q46167132-68CA1F75-21CA-4556-90E1-372FB1D72976

Q46167132-887134C4-865D-4A57-820D-4D16E531121E

Q46167132-973FEF51-8755-4851-9A35-832107EF4946

Q46167132-98DCDB66-24FB-4486-A87C-17584151697A

P2860

Q46167132-000F2391-3FBE-4626-B2B2-AF5102FE028A

Q46167132-03DCC87E-382A-474D-B02F-0123FB46620A

Q46167132-06E26C6E-877B-466A-BE03-814464033E77

Q46167132-16EEC1AC-7C6C-4BFB-9D82-A2A1651356FC

Q46167132-1DF81574-FBC9-4C92-9F08-69F0C40729A5

Q46167132-20428FB7-69C7-48BE-895B-9F18664EA687

Q46167132-3AAAA9A8-9B92-4141-A834-0F5A282DCA50

Q46167132-5C787878-52CB-44F7-B0FD-D1E9AE362DF8

Q46167132-5D467B3B-C0CD-42C4-868C-6B5945D1F064

Q46167132-6B8FBE64-C012-431A-9ED9-8E5B63E6D5B0

P304

Q46167132-92D94C62-DD99-4E04-A9CF-C40B4B47064B

P31

Q46167132-227590C1-C4EB-4E89-858B-575FC65930E7

P356

Q46167132-53243C7B-5CF6-430D-8CA9-8FB659E81E21

P407

Q46167132-54E54DC5-AAFD-41C3-A7CB-9998B90290BC

P433

Q46167132-E5A81AE7-3CE0-4412-BD12-EE51CA5D3BBD

P478

Q46167132-5A68BBAC-CD0F-4B14-8724-67FD6CB66F31

P577

Q46167132-EFEECF05-AFC2-4C2B-9161-B8A9F0F68366

P5875

Q46167132-EE2FDE06-F6E1-4BBB-B9E2-D6EE2F80E472

P698

Q46167132-D92480AE-A764-4AED-AB33-1A2308C4DB99

P921

Q46167132-CE0192CC-4794-4EBB-9D33-1425985CF2C4

P356

P1433

P1476

Beneficial effects of sorafeni ...... pertensive and cirrhotic rats.

@en

P2093

Carolina Tiani

http://www.w3.org/2001/XMLSchema#string

Ester Garcia-Pras

http://www.w3.org/2001/XMLSchema#string

Jaime Bosch

http://www.w3.org/2001/XMLSchema#string

Marc Mejias

http://www.w3.org/2001/XMLSchema#string

Mercedes Fernandez

http://www.w3.org/2001/XMLSchema#string

Rosa Miquel

http://www.w3.org/2001/XMLSchema#string

P2860

Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.

The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.

Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.

P304

1245-1256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22758

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23771807

http://www.w3.org/2001/XMLSchema#string

P698

19137587

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis